Prescribing unapproved peptides? Here's what physicians need to know about the legal risks

The peptide craze is hitting medicine hard, but physicians who prescribe unapproved compounds are exposing themselves to serious legal and regulatory consequences. While FDA-approved drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound/Mounjaro) are generally safe to prescribe, many other peptides being produced by compounding pharmacies lack FDA approval — and that gap carries major liability.

In a recent policy shift, the FDA announced it would pause enforcement against pharmacies compounding six specific bulk peptide substances, a move affirmed by the White House and formalized in the Federal Register on Oct. 30, 2026. But this federal reprieve doesn't shield physicians from state-level action — state medical boards and attorneys general can still pursue independent enforcement regardless of federal policy.

Key Takeaways:

• Sourcing peptides from unverified online vendors or overseas suppliers can lead to federal criminal indictment
• Marketing unapproved peptides as treatments without solid scientific evidence opens the door to civil fraud and consumer protection lawsuits
• Physicians must obtain informed consent disclosing a peptide's experimental status and lack of FDA approval
• Inadequate documentation of consent can result in malpractice claims if adverse events occur

Why it matters: As peptide use grows in clinical practice, physicians need to understand that regulatory gray areas don't equal legal safety — the consequences can range from license loss to criminal prosecution.